

## Market data

EPIC/TKR	BUR
Price (p)	929.5
12m High (p)	969.5
12m Low (p)	310.0
Shares (m)	208.2
Mkt Cap (£m)	1,936
Total Assets (\$m)	1,050
Free Float*	86%
Market	AIM

\*As defined by AIM Rule 26

## Description

Burford Capital is a leading global finance and professional services firm focusing on law. Its businesses include litigation finance and risk management, asset recovery and a wide range of legal finance and advisory activities.

## Company information

CEO	Christopher Bogart
CIO	Jonathan Molot
Chairman	Sir Peter Middleton
	+1 (212) 235-6820
	<a href="http://www.burfordcapital.com">www.burfordcapital.com</a>

## Key shareholders

Directors	14%
Invesco Perpetual	25.0%
Woodford Investments	10.0%
Aberdeen Asset	4.9%

## Next event

16 Jun-17	Final dividend paid
27 Jul-17	Interim results

## Analyst

Brian Moretta	020 7194 7622
	<a href="mailto:bm@hardmanandco.com">bm@hardmanandco.com</a>

## Burford Capital

### Positive judgement from the secondary market

Burford has announced a further sale from the Petersen case, the third in the last six months. On this occasion, they have sold 15% of the exposure for \$66m, giving an implied value on the whole case of \$440m. This is a 10% uplift on the value given by the previous sales, which was \$400m. Having reduced their retained exposure to 75%, Burford have made commitments to keep at least 65% until the end of 2018 and at least 50.1% beyond that.


- ▶ **Earnings:** There will be a significant additional realised gain from the sale, which Hardman & Co estimate at \$60m. There will be an effect on unrealised gains too, with our overall revenue forecast for 2017E increased by \$99m. There is no effect on earnings estimated beyond 2017.
- ▶ **Balance sheet:** The sale will bring another \$66m of cash back onto the balance sheet, which gives Burford plenty of capacity for investment when added to the £175m (\$225m) proceeds of the recent bond issue. The increased asset value has mechanically reduced our RoE estimates for 2018E and 2019E.
- ▶ **Valuation:** With the sale only affecting 2017E earnings, this has little effect on Burford's prospective P/E which remains good value despite the strong share price performance. The P/E for 2019E is only 14.6 times. The 2019E RoE becomes 16.6% on a larger book value, with strong growth which suggests excellent metrics all round.
- ▶ **Risks:** The investment portfolio is still diversified, with exposure to over 500 claims, but retains some very large investments, which means revenue may be volatile. As the company matures, we would expect that to decrease but not to disappear. The Petersen case shows that this volatility is not simply a negative.
- ▶ **Investment summary:** Burford has already demonstrated an impressive ability to deliver good returns in a growing market, whilst investing its capital base. As the invested capital continues to grow, the litigation investment business will continue to produce strong earnings growth.

## Financial summary and valuation

Year end Dec (\$m)	2014	2015	2016	2017E	2018E	2019E
Revenue	82.0	103.0	163.4	332.1	229.0	271.4
Operating Profit	60.7	77.2	124.4	280.0	168.3	201.0
Reported net income	45.4	64.5	108.3	248.0	136.2	167.9
Underlying net income	53.0	64.5	114.2	248.0	136.2	167.9
Underlying Return on Equity	12.1%	16.0%	22.2%	35.8%	15.9%	16.6%
Underlying EPS (\$)	0.26	0.32	0.55	1.19	0.65	0.81
Statutory EPS (\$)	0.22	0.32	0.53	1.19	0.65	0.81
Dividend per share (\$)	0.07	0.08	0.09	0.11	0.12	0.14
Yield	0.6%	0.7%	0.8%	0.9%	1.0%	1.2%
NAV per share (\$)	1.87	2.12	2.22	3.14	3.80	4.60
P/E (x) (underlying)	45.6	37.5	21.5	9.9	18.1	14.6
Price/NAV (x)	6.3	5.6	5.3	3.8	3.1	2.6


Source: Hardman & Co Research

Revenue




- ▶ Long term growth depends on pace of investment and conclusions
- ▶ Accelerated investment in 2016 will boost 2017 and 2018 revenue
- ▶ 2017 figures boosted by sales from Petersen case
- ▶ GKC acquisition adds revenue from 2017 onwards

Interest Cover



- ▶ No debt prior to 2014
- ▶ Retail bond issues in 2014, 2016 and 2017
- ▶ \$43.75m loan note issued for GKC acquisition now redeemed
- ▶ 2014 issue was mid-year so only partial accrual of coupon

Eps and dividend



- ▶ 2017 results boosted by sales from Petersen case
- ▶ Full effect of large single \$100m investment coming through properly in late 2016 and into 2017
- ▶ Some large single claims may introduce volatility in the future

Source: Company data; Hardman & Co Research

## Effect of transaction

We have discussed the Petersen case in detail in our notes of 27 January 2017 and 20 March 2017. Readers who are not familiar with the case's history are encouraged to read those for fuller information.

It is worth reiterating a couple of points for investors:

- ▶ Burford do not disclose the valuation of any individual investments. We do not know what the valuation of the Petersen case was in the year end results, so we can only estimate the gains on these transactions.
- ▶ We don't know how much of the valuation uplift Burford will incorporate into its unrealised gains. Previously it has indicated that the sales were insufficient to justify using the transaction price as the value for the whole investment. In particular, it has stated and repeats in this announcement, that it has not consulted its auditors yet.

This is Burford's third sale, and the largest yet, for the Petersen case. In the previous transactions, it sold 10% of its exposure, and has sold an additional 15%, leaving a 75% retention. The implied valuation based on the latest transaction is \$440m.

For our previous 2017E figures Hardman & Co assumed a prior (year end) valuation of \$40m, giving an estimated realised gain of \$36m. We assumed an unrealised gain of the same amount as a 10% move towards the implied valuation.

If we use the same base valuation, that suggests an additional realised gain of \$60m for the latest transaction.

Burford's disclosure policy is well justified, but means that estimating the unrealised gain is, to an analyst's frustration, little more than an exercise in educated guesswork. We can justify any figure up to \$300m, but Burford management has historically been quite conservative. As they had sold 10% previously, we assumed a movement of 10% towards the valuation. As the sale level is now 25%, we'll do the same, implying a total estimated unrealised gain of \$75m, or an increase of \$39m. (Investors should note that some of the previously assumed unrealised gain has now been realised).

This gives an uplift to 2017E revenues of \$99m, or a 67% uplift to after tax earnings to \$248m. There is no effect on estimates beyond that, though the increased asset value does lower the return on equity forecasts.

### Summary

This is clearly another positive for investors. In cash terms the realised gains make the Petersen case Burford's most successful investment to date, even if they never receive another penny. That investors are willing to invest into it suggests optimism from them about its eventual outcome. We do need to caution that, as an investment in a single case, the outcome remains somewhat binary. A successful outcome could give Burford further gains. However, if it fails the write-down will have significant negative effect on that year's earnings, though the balance sheet and portfolio is sufficiently strong and diverse that such a write-down should not affect Burford's earnings prospects other than that.

## Financials and Forecast

We note, as before, that our revenue forecasts largely reflect an expected average based on analysis of Burford's track record. Individual cases are binary in nature and, therefore, impossible to explicitly forecast. Burford has a few large cases, including the Petersen claim, which may have a significant but impossible to forecast impact on the results.

Summary financials						
Year end Dec (\$m)	2014	2015	2016	2017E	2018E	2019E
Revenue	82.0	103.0	163.4	332.1	229.0	271.4
Expenses	21.3	25.8	39.0	52.0	60.7	70.4
<b>Operating Profit</b>	<b>60.7</b>	<b>77.2</b>	<b>124.4</b>	<b>280.0</b>	<b>168.3</b>	<b>201.0</b>
Finance cost	3.7	9.3	14.1	22.9	26.9	26.9
Exceptional items	-9.7	0.0	-5.9	0.0	0.0	0.0
<b>Reported pre-tax</b>	<b>47.3</b>	<b>67.9</b>	<b>104.1</b>	<b>256.8</b>	<b>141.1</b>	<b>173.8</b>
Reported taxation	-0.7	-2.2	4.8	-8.8	-4.9	-5.9
Minorities	1.2	1.2	0.6	0.0	0.0	0.0
<b>Underlying net income</b>	<b>53.0</b>	<b>64.5</b>	<b>114.2</b>	<b>248.0</b>	<b>136.2</b>	<b>167.9</b>
Statutory net income	45.4	64.5	108.3	248.0	136.2	167.9
<b>Underlying Basic EPS (\$)</b>	<b>0.26</b>	<b>0.32</b>	<b>0.56</b>	<b>1.19</b>	<b>0.65</b>	<b>0.81</b>
Statutory Basic EPS (\$)	0.22	0.32	0.53	1.19	0.65	0.81
Dividend (\$)	0.07	0.08	0.09	0.11	0.12	0.14
<b>Balance sheet</b>						
Total equity	382.7	433.1	462.2	654.8	790.9	958.8
Invested Capital	207.5	252.9	394.3	621.6	750.8	906.3
Fair Value Balance	266.8	334.2	559.7	932.7	1,169.3	1,451.3
<b>Total Assets</b>	<b>533.2</b>	<b>608.7</b>	<b>826.4</b>	<b>1,259.5</b>	<b>1,395.7</b>	<b>1,563.6</b>
NAV Per share (\$)	1.87	2.12	2.22	3.14	3.80	4.60
<b>Return on Equity</b>	<b>12.4%</b>	<b>15.8%</b>	<b>21.0%</b>	<b>35.8%</b>	<b>15.9%</b>	<b>16.6%</b>

Source: Hardman & Co, £1=\$1.27

## Disclaimer

*Hardman & Co provides professional independent research services. Whilst every reasonable effort has been made to ensure that the information in the research is correct, this cannot be guaranteed.*

*The research reflects the objective views of the analysts named on the front page. However, the companies or funds covered in this research may pay us a fee, commission or other remuneration in order for this research to be made available. A full list of companies or funds that have paid us for coverage within the past 12 months can be viewed at <http://www.hardmanandco.com/>*

*Hardman & Co has a personal dealing policy which debars staff and consultants from dealing in shares, bonds or other related instruments of companies which pay Hardman for any services, including research. They may be allowed to hold such securities if they were owned prior to joining Hardman or if they were held before the company appointed Hardman. In such cases sales will only be allowed in limited circumstances, generally in the two weeks following publication of figures.*

*Hardman & Co does not buy or sell shares, either for its own account or for other parties and neither does it undertake investment business. We may provide investment banking services to corporate clients.*

*Hardman & Co does not make recommendations. Accordingly, we do not publish records of our past recommendations. Where a Fair Value price is given in a research note this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities/companies but has no scheduled commitment and may cease to follow these securities/companies without notice.*

*Nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell securities by us.*

*This information is not tailored to your individual situation and the investment(s) covered may not be suitable for you. You should not make any investment decision without consulting a fully qualified financial adviser.*

*This report may not be reproduced in whole or in part without prior permission from Hardman & Co.*

*Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority (FCA) under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259. However, the information in this research report is not FCA regulated because it does not constitute investment advice (as defined in the Financial Services and Markets Act 2000) and is provided for general information only.*

*Hardman & Co Research Limited (trading as Hardman & Co)  
35 New Broad Street  
London  
EC2M 1NH  
T +44 (0) 207 194 7622*

*Follow us on Twitter @HardmanandCo*

*(Disclaimer Version 2 – Effective from March 2017)*

## Hardman Team

### Management Team

+44 (0)20 7194 7622

John Holmes	jh@hardmanandco.com	+44 (0)207 194 7629	Chairman
Keith Hiscock	kh@hardmanandco.com	+44 (0)207 194 7630	CEO

### Marketing / Investor Engagement

+44 (0)20 7194 7622

Richard Angus	ra@hardmanandco.com	+44 (0)207 194 7635
Max Davey	md@hardmanandco.com	+44 (0)207 194 7622
Antony Gifford	ag@hardmanandco.com	+44 (0)207 194 7622
Vilma Pabilionyte	vp@hardmanandco.com	+44 (0)207 194 7637
Gavin Laidlaw	gl@hardmanandco.com	+44 (0)207 194 7627
Ann Hall	ah@hardmanandco.com	+44 (0)207 194 7622

### Analysts

+44 (0)20 7194 7622

#### Agriculture

Doug Hawkins	dh@hardmanandco.com
Yingheng Chen	yc@hardmanandco.com
Thomas Wigglesworth	tcw@hardmanandco.com

#### Bonds

Brian Moretta	bm@hardmanandco.com
Mark Thomas	mt@hardmanandco.com
Chris Magennis	cm@hardmanandco.com

#### Building & Construction

Tony Williams	tw@hardmanandco.com
Mike Foster	mf@hardmanandco.com

#### Consumer & Leisure

Mike Foster	mf@hardmanandco.com
Steve Clapham	sc@hardmanandco.com
Jason Streets	js@hardmanandco.com

#### Financials

Brian Moretta	bm@hardmanandco.com
Mark Thomas	mt@hardmanandco.com

#### Life Sciences

Martin Hall	mh@hardmanandco.com
Gregoire Pave	gp@hardmanandco.com
Dorothea Hill	dmh@hardmanandco.com

#### Media

Derek Terrington	dt@hardmanandco.com
------------------	---------------------

#### Mining

Paul Singer	if@hardmanandco.com
-------------	---------------------

#### Oil & Gas

Angus McPhail	am@hardmanandco.com
---------------	---------------------

#### Property

Mike Foster	mf@hardmanandco.com
-------------	---------------------

#### Services

Mike Foster	mf@hardmanandco.com
-------------	---------------------

#### Special Situations

Steve Clapham	sc@hardmanandco.com
Paul Singer	ps@hardmanandco.com

#### Tax Enhanced Services

Brian Moretta	bm@hardmanandco.com
Chris Magennis	cm@hardmanandco.com

#### Utilities

Nigel Hawkins	nh@hardmanandco.com
---------------	---------------------

#### Hardman & Co

35 New Broad Street  
London  
EC2M 1NH

Tel: +44(0)20 7194 7622

www.hardmanandco.com

